Company / SG&A per Share
CRISPR Therapeutics AG SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.86
FY2025
5-year range
$0.86 / $1.35
FY2021-FY2025
Trend
-5.9%
vs FY2024
Sector context
#135 of 208
Health Care
What the data says
At $0.86, CRISPR Therapeutics AG's sg&a per share ranks #74 of 208 in the Health Care sector. SG&A per Share has declined for 5 consecutive years, from $1.41 in FY2020 to $0.86 in FY2025.
Based on SEC 10-K filings.
0.86 in FY2025 with a 5-year CAGR of -9.5%.
Improved from $0.97 to $0.86 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -13.6%
- 5-Year CAGR
- -9.5%
- 10-Year CAGR
- -
Sector benchmark
#74 of 208 in Health CareTop 35% of 208This company $0.86 Sector average $29.78
▼
-97.1% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's sg&a per share has declined for 5 consecutive years.
- In FY2025, sg&a per share decreased 5.9% year-over-year.
- Ranks #135 out of 208 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.86 | -5.9% |
| FY2024 | $0.91 | -6.0% |
| FY2023 | $0.97 | -27.1% |
| FY2022 | $1.33 | -1.3% |
| FY2021 | $1.35 | -4.4% |
| FY2020 | $1.41 | +15.2% |
| FY2019 | $1.22 | +2.9% |
| FY2018 | $1.19 | +31.8% |
| FY2017 | $0.90 | -83.9% |
| FY2016 | $5.62 | +111.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026